Exchange: NASDAQ·Updated 10:59 AM EDT

LKFTLakefront Biotherapeutics NV - ADR

$29.06
$0.01
(0.03%)
Today
EarningsAug 10
Mkt Cap$1.91B
Vol30,011.00
News
all
press releases
News Placeholder
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. This press release features multimedia...
Business Wire
<
...
1
>

Advertisement|Remove ads.